A Phase 3 interventional study of DFN-15 Active and DFN-15 Placebo in Migraine Headache, sponsored by BioDelivery Sciences International. Completed at 45 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-01-10.
Sponsored by BioDelivery Sciences International · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 696 studies in Migraine Disorders with a site in United States — 93 open to participants now, 115 under way, 27 of them phase 3. Migraine Disorders · United States.
Among the 696 studies in Migraine Disorders with a site in United States, this one is the 85th largest by enrollment of the 609 interventional ones that give a count, is one of 43 that started in 2016, is one of 136 in phase 3, and was the 329th registered.
1,658 studies on the registry are indexed under Migraine Disorders; 339 are open to participants now.
Browse Migraine Disorders studies →93 of the 696 studies in Migraine Disorders with a site in United States are open now. Recruiting first, the newest first:
Salvia BioElectronics · Sites in United States
Ages 22–84
University of Colorado, Denver · Sites in United States
Ages 12–17
Columbia University · Sites in United States
Ages 18–55
TriGemX Bio, Inc. · Sites in United States
Ages 18–75
University of North Carolina, Chapel Hill · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
696 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 66 · Phase 2 113 · Phase 3 151 · Phase 4 101
First in 1999; this study’s year is marked. 43 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 622 is above the median of 80 across 1,269 interventional studies indexed under Migraine Disorders.
Median enrollment 78 across the 609 interventional studies, 195 across the 84 observational. Of the 526 that completed or were terminated, 305 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
344 of 696 have an industry lead sponsor. The 10 most frequent:
BioDelivery Sciences International is the lead sponsor of 21 studies on the registry; 1 is open to participants now.
BioDelivery Sciences International has 2 studies filed under Migraine Disorders — fewer than ten, so there is no comparison to draw.
47 of the studies in Migraine Disorders with a site in United States that are under way reach primary completion within a year, 11 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06641466Phase 3PfizerA Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine | 2026-11-29 |
| NCT07645924Phase 3TriGemX Bio, Inc.A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine | 2027-02 |
| NCT05598723Phase 3Naval Medical Center Camp LejeuneBOTOX® vs. XEOMIN® for Chronic Migraine | 2027-02-24 |
| NCT07018700Phase 3Merz Therapeutics GmbHA Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine | 2027-03 |
| NCT07018713Phase 3Merz Therapeutics GmbHA Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine | 2027-03 |
Add all 47 to your calendar (.ics) → With an account.
Among the 696 studies in Migraine Disorders with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Efficacy, Tolerability, and Safety of DFN-15 in episodic migraine with or without aura, being conducted at multiple centers in the United States.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects who are willing and able to:
Exclusion Criteria:
Medication overuse:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DFN-15 Active
Drug: DFN-15 Active
DFN-15 Placebo
Other: DFN-15 Placebo
Also known as: Celecoxib Oral Solution
Percentage of Subjects Who Are Pain-free at 2 Hours Postdose (DB1)
Percentage of subjects who were pain-free 2 hours postdose compared between DFN-15 and placebo in the DB1 period (defined as a reduction from predose moderate \[Grade 2\] or severe \[Grade 3\] pain to none \[Grade 0\]) during DB1.
Time frame: 2 hours post dose
Percentage of Subjects Who Are Free From Their MBS at 2 Hours Postdose (DB1)
Percentage of subjects who are free from their most bothersome symptom (MBS) among nausea, photophobia, and phonophobia at 2 hours postdose during DB1.
Time frame: 2 hours post dose
Freedom From Nausea, Photophobia, and Phonophobia Postdose (DB1 and DB2)
The percentage of subjects who were free from nausea, photophobia, and phonophobia at 15, 30, and 45 minutes and 1, 1.5, 2, 4, and 24 hours postdose during each DB treatment period were summarized by symptom, treatment group, and time point.
Time frame: 15 minutes through 24 hours
Time to Headache Pain Relief Postdose (DB1 and DB2)
Time frame: 2 hours postdose
Time to Headache Pain Freedom Postdose (DB1 and DB2)
Time frame: 2 hours postdose
Headache Pain Relief Postdose (DB1 and DB2)
Headache pain relief during postdose in DB1 was defined as a reduction from moderate or severe pain at predose reduced to mild or none postdose, and for DB2 as moderate or severe pain at predose reduced to mild or none postdose, or mild pain at predose reduced to none postdose. Outcome measure shows percentage of subjects experiencing headache pain relief by time point.
Time frame: 15 minutes to 24 hours postdose
Headache Pain Freedom Postdose (DB1 and DB2)
The percentage of subjects who were pain-free at 15, 30, and 45 minutes and 1, 1.5, 2 (DB2), and 4, and 24 hours postdose during each DB treatment period were summarized by treatment group.
Time frame: 15 minutes to 24 hours postdose
Absence of Screening MBS at Time Points Postdose (DB1 and DB2)
The percentage of subjects with their Screening MBS (most bothersome symptoms) among nausea, photophobia, and phonophobia (from eDiary data collection) absent at 15, 30, and 45 minutes and 1, 1.5, 2 (DB2 period), 4, and 24 hours postdose during each DB treatment period were summarized by treatment group and time point.
Time frame: 15 minutes to 24 hours postdose
Change in Functional Disability Score Postdose (DB1 and DB2)
The values of the functional disability scale were: 0=no disability, able to function normally; 1=performance of daily activities mildly impaired, can still do everything but with difficulty; 2=performance of daily activities moderately impaired, unable to do some things; 3=performance of daily activities severely impaired, cannot do all or most things, bed rest may be necessary. A decrease in values indicates improvement from baseline.
Time frame: 2 to 24 hours postdose
Headache Pain Freedom Among Subjects With Cutaneous Allodynia (DB1 and DB2)
The percentage of subjects who were pain-free at 2 and 4 hours postdose during each DB treatment period among those subjects reporting cutaneous allodynia before dosing were summarized by treatment group and time point.
Time frame: 2 to 4 hours postdose
Headache Pain Freedom Among BMI Category (DB1 and DB2)
The percentage of subjects who were pain-free at 2 and 4 hours postdose whose BMI was \<30 kg/m2 vs. subjects whose BMI was ≥30 kg/m2 during each DB treatment period were summarized by treatment group and time point.
Time frame: 2 to 4 hours postdose
Headache Pain Recurrence Postdose (DB1 and DB2)
Headache pain recurrence was defined as pain-free at 2 hours postdose with pain reported as mild, moderate, or severe at 24 hours postdose. This outcome measure shows percentage of subjects who reported pain-free status and 2 hours postdose but subsequently reported recurrent pain at 24 hours postdose.
Time frame: 2 to 24 hours postdose
Sustained Headache Pain Relief Postdose (DB1 and DB2)
Sustained headache pain relief was defined as pain relief at 2 hours postdose with no use of rescue medication and no worsening of headache pain within 2 to 24 hours postdose. This outcome measure shows the percentage of subjects who reported pain relief at 2 hours postdose with no use of rescue medication or worsening of headache pain through 24 hours postdose.
Time frame: 2 to 24 hours postdose
Sustained Headache Pain Freedom Postdose (DB1 and DB2)
Sustained headache pain freedom was defined as pain-free at 2 hours postdose, with no use of rescue medication and no recurrence of headache pain within 2 to 24 hours postdose. This outcome measure shows percentage of subjects who were pain-free at 2 hours postdose without the use of rescue medication or recurrence of headache pain through 24 hours postdose.
Time frame: 2 to 24 hours postdose
Use of Rescue Medication Postdose (DB1 and DB2)
The percentage of subjects who used rescue mediation after 2 hours (2 to 24 hours) postdose compared between DFN-15 and placebo in each DB period.
Time frame: 2 to 24 hours postdose
Subject-Rated Treatment Satisfaction Postdose (DB1 and DB2)
Subject-rated treatment overall satisfaction was based on a 7-point scale at 2 and 4 hours postdose during each DB treatment period. The difference between the subject-rated study drug treatment satisfaction score at 2 and 4 hours postdose and the baseline PPMQ-R (Patient Perception of Migraine Questionnaire) response for the same question were summarized by treatment group (global satisfaction item at baseline asked about the subject's usual migraine treatment). The possible values of the subject treatment satisfaction scale were: 1=very satisfied, 2=satisfied, 3=somewhat satisfied, 4=neither satisfied nor dissatisfied, 5=somewhat dissatisfied, 6=dissatisfied, 7=very dissatisfied. A decrease in values indicates improvement from baseline.
Time frame: 2 to 4 hours postdose
Subject-Rated Treatment Satisfaction at 24 Hours Postdose - PPMQ-R (DB1 and DB2)
Patient Perception of Migraine Questionnaire-Revised had 30 questions assessing subject's satisfaction with migraine medication, including 3 global items \& 4 subscales (i.e., efficacy, function, ease of use, tolerability). A 5-point scale (1-Not At All to 5-Extremely) was used for tolerability subscale questions; a 7-point scale (1-Very Satisfied to 7-Very Dissatisfied) was used for all other subscales and global items. Total score was average of efficacy/function/ease of use subscale scores. Each subscale \& total scores were transformed to range from 0-100, with higher scores indicating better satisfaction or tolerability. Total raw score/global items were not transformed. The total raw score could range from 17 (min) to 119 (max), with lower scores indicating better satisfaction. Change from baseline scores at 24-hour-postdose for each subscale score, global item score, total score, \& total raw score were summarized by treatment group below.
Time frame: 24 hours postdose
| Milestone | Placebo | DFN-15 |
|---|---|---|
| Started | 311 | 311 |
| Not completed | 43 | 42 |
| Completed | 266 | 265 |
| Not completed | 45 | 46 |
| Milestone | Placebo | DFN-15 |
|---|---|---|
| Started | 278 | 267 |
| Not completed | 16 | 20 |
| Completed | 249 | 242 |
| Not completed | 29 | 25 |
Percentage of subjects who were pain-free 2 hours postdose compared between DFN-15 and placebo in the DB1 period (defined as a reduction from predose moderate \[Grade 2\] or severe \[Grade 3\] pain to none \[Grade 0\]) during DB1.
| percentage of subjects | Placebo LOCF | DFN-15 LOCF | Placebo OC | DFN-15 OC |
|---|---|---|---|---|
| Percentage of Subjects Who Are Pain-free at 2 Hours Postdose (DB1) | 21.7 (16.8 to 27.1) | 35.6 (30.0 to 41.6) | 22.1 (17.2 to 27.7) | 35.8 (30.1 to 41.8) |
Percentage of subjects who are free from their most bothersome symptom (MBS) among nausea, photophobia, and phonophobia at 2 hours postdose during DB1.
| percentage of subjects | Placebo LOCF | DFN-15 LOCF | Placebo OC | DFN-15 OC |
|---|---|---|---|---|
| Percentage of Subjects Who Are Free From Their MBS at 2 Hours Postdose (DB1) | 44.8 (38.3 to 51.5) | 57.8 (51.1 to 64.2) | 45.4 (38.8 to 52.1) | 58.3 (51.6 to 64.8) |
The percentage of subjects who were free from nausea, photophobia, and phonophobia at 15, 30, and 45 minutes and 1, 1.5, 2, 4, and 24 hours postdose during each DB treatment period were summarized by symptom, treatment group, and time point.
| percentage of subjects | DB1 Placebo (Nausea) | DB1 DFN-15 (Nausea) | DB1 Placebo (Photophobia) | DB1 DFN-15 (Photophobia) | DB1 Placebo (Phonophobia) | DB1 DFN-15 (Phonophobia) | DB2 Placebo (Nausea) | DB2 DFN-15 (Nausea) | DB2 Placebo (Photophobia) | DB2 DFN-15 (Photophobia) | DB2 Placebo (Phonophobia) | DB2 DFN-15 (Phonophobia) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 15 minutes postdose | 16.8 (10.8 to 24.3) | 15.7 (10.0 to 23.0) | 8.8 (5.4 to 13.5) | 9.6 (5.9 to 14.4) | 15.7 (10.7 to 21.9) | 10.5 (6.4 to 16.1) | 14.5 (8.5 to 22.5) | 13.7 (7.7 to 22.0) | 7.5 (4.2 to 12.2) | 8.0 (4.6 to 12.9) | 8.5 (4.5 to 14.4) | 10.3 (6.0 to 16.1) |
| 30 minutes postdose | 33.6 (25.9 to 41.9) | 32.9 (25.3 to 41.1) | 13.0 (9.0 to 18.1) | 20.1 (15.1 to 25.9) | 26.0 (20.0 to 32.9) | 24.6 (18.6 to 31.4) | 26.9 (19.2 to 35.8) | 31.4 (22.7 to 41.2) | 14.4 (9.8 to 20.0) | 21.9 (16.4 to 28.4) | 15.6 (10.2 to 22.3) | 27.4 (20.8 to 34.9) |
| 45 minutes postdose | 43.8 (35.6 to 52.3) | 45.3 (37.1 to 53.7) | 20.2 (15.2 to 25.9) | 30.6 (24.7 to 37.0) | 26.7 (20.6 to 33.5) | 35.8 (29.0 to 43.0) | 41.8 (32.9 to 51.1) | 44.3 (34.7 to 54.3) | 22.1 (16.6 to 28.4) | 36.2 (29.5 to 43.3) | 25.8 (19.1 to 33.4) | 38.6 (31.1 to 46.4) |
| 1 hour postdose | 49.3 (41.0 to 57.7) | 56.8 (48.4 to 64.9) | 26.5 (21.0 to 32.6) | 38.9 (32.6 to 45.5) | 38.3 (31.4 to 45.5) | 45.0 (37.8 to 52.4) | 52.5 (43.2 to 61.6) | 51.9 (42.0 to 61.7) | 27.9 (21.9 to 34.6) | 43.7 (36.7 to 50.9) | 34.2 (26.8 to 42.2) | 44.0 (36.3 to 51.9) |
| 1.5 hours postdose | 58.5 (50.1 to 66.6) | 63.5 (55.2 to 71.3) | 36.0 (29.9 to 42.5) | 47.4 (40.9 to 54.0) | 47.2 (40.1 to 54.4) | 50.8 (43.5 to 58.1) | 60.2 (50.9 to 68.9) | 67.3 (57.5 to 76.0) | 35.4 (28.9 to 42.4) | 52.5 (45.3 to 59.6) | 43.2 (35.3 to 51.4) | 56.3 (48.4 to 63.9) |
| 2 hours postdose | 62.2 (53.8 to 70.0) | 67.6 (59.4 to 75.0) | 44.4 (37.9 to 50.9) | 58.3 (51.7 to 64.7) | 54.5 (47.3 to 61.5) | 61.1 (53.9 to 68.1) | 66.9 (57.9 to 75.1) | 69.2 (59.5 to 77.7) | 45.9 (39.0 to 52.9) | 64.0 (56.9 to 70.6) | 48.7 (40.6 to 56.8) | 67.7 (60.0 to 74.7) |
| 4 hours postdose | 75.5 (67.8 to 82.1) | 75.0 (67.2 to 81.7) | 61.2 (54.7 to 67.3) | 69.9 (63.6 to 75.7) | 72.9 (66.2 to 78.9) | 71.5 (64.6 to 77.8) | 74.2 (65.6 to 81.6) | 85.0 (76.9 to 91.2) | 62.8 (55.8 to 69.4) | 78.1 (71.7 to 83.6) | 59.0 (50.8 to 66.8) | 76.2 (69.0 to 82.4) |
| 24 hours postdose | 91.4 (85.7 to 95.3) | 90.6 (84.7 to 94.8) | 85.2 (80.1 to 89.4) | 85.7 (80.6 to 89.9) | 89.7 (84.6 to 93.5) | 85.1 (79.3 to 89.8) | 87.1 (79.9 to 92.4) | 93.5 (87.1 to 97.4) | 84.6 (79.0 to 89.2) | 91.6 (86.9 to 95.0) | 81.5 (74.6 to 87.3) | 90.5 (85.1 to 94.5) |
| minutes | Placebo DB1 | DFN-15 DB1 | Placebo DB2 | DFN-15 DB2 |
|---|---|---|---|---|
| Time to Headache Pain Relief Postdose (DB1 and DB2) | 59.5 ± 29.82 | 68.9 ± 43.67 | 55.3 ± 29.22 | 62.1 ± 29.58 |
| minutes | Placebo DB1 | DFN-15 DB1 | Placebo DB2 | DFN-15 DB2 |
|---|---|---|---|---|
| Time to Headache Pain Freedom Postdose (DB1 and DB2) | 66.6 ± 32.31 | 68.5 ± 31.01 | 68.8 ± 25.06 | 80.8 ± 25.80 |
Headache pain relief during postdose in DB1 was defined as a reduction from moderate or severe pain at predose reduced to mild or none postdose, and for DB2 as moderate or severe pain at predose reduced to mild or none postdose, or mild pain at predose reduced to none postdose. Outcome measure shows percentage of subjects experiencing headache pain relief by time point.
| percentage of subjects | Placebo DB1 | DFN-15 DB1 | Placebo DB2 | DFN-15 DB2 |
|---|---|---|---|---|
| 15 minutes postdose | 16.6 (12.1 to 22.0) | 13.4 (9.4 to 18.3) | 10.9 (7.1 to 15.8) | 11.7 (7.8 to 16.6) |
| 30 minutes postdose | 28.9 (23.4 to 34.9) | 32.2 (26.6 to 38.2) | 27.5 (21.9 to 33.7) | 31.6 (25.7 to 38.0) |
| 45 minutes postdose | 40.2 (34.2 to 46.5) | 46.5 (40.4 to 52.6) | 37.1 (31.0 to 43.5) | 47.7 (41.2 to 54.2) |
| 1 hour postdose | 45.1 (38.9 to 51.4) | 56.8 (50.7 to 62.7) | 43.8 (37.4 to 50.3) | 56.1 (49.5 to 62.5) |
| 1.5 hours postdose | 55.2 (48.9 to 61.4) | 70.0 (64.1 to 75.3) | 53.3 (46.8 to 59.7) | 66.4 (60.0 to 72.4) |
| 2 hours postdose | 60.5 (54.3 to 66.4) | 74.5 (69.0 to 79.6) | 60.7 (54.2 to 66.8) | 74.4 (68.3 to 79.8) |
| 4 hours postdose | 75.2 (69.5 to 80.3) | 79.6 (74.4 to 84.2) | 75.0 (69.1 to 80.3) | 82.2 (77.5 to 87.4) |
| 24 hours postdose | 92.5 (88.7 to 95.4) | 92.4 (88.7 to 95.3) | 89.0 (84.4 to 92.6) | 93.8 (89.9 to 96.5) |
The percentage of subjects who were pain-free at 15, 30, and 45 minutes and 1, 1.5, 2 (DB2), and 4, and 24 hours postdose during each DB treatment period were summarized by treatment group.
| percentage of subjects | Placebo DB1 | DFN-15 DB1 | Placebo DB2 | DFN-15 DB2 |
|---|---|---|---|---|
| 15 minutes postdose | 1.3 (0.3 to 3.7) | 0.4 (0.0 to 2.2) | 1.4 (0.3 to 3.9) | 0.9 (0.1 to 3.2) |
| 30 minutes postdose | 3.6 (1.6 to 6.6) | 3.0 (1.3 to 5.8) | 6.4 (3.6 to 10.3) | 6.8 (4.0 to 10.9) |
| 45 minutes postdose | 8.6 (5.5 to 12.7) | 11.1 (7.6 to 15.4) | 11.7 (7.9 to 16.4) | 12.7 (8.7 to 17.6) |
| 1 hour postdose | 12.8 (9.0 to 17.6) | 17.9 (13.6 to 23.0) | 15.8 (11.5 to 21.1) | 23.2 (18.0 to 29.1) |
| 1.5 hours postdose | 17.4 (13.0 to 22.5) | 27.1 (21.9 to 32.8) | 25.2 (19.9 to 31.2) | 36.1 (30.0 to 42.6) |
| 2 hours postdose | — | — | 31.1 (25.4 to 37.4) | 46.2 (39.8 to 52.8) |
| 4 hours postdose | 44.4 (38.3 to 50.6) | 56.4 (50.3 to 62.3) | 50.0 (43.6 to 56.4) | 61.9 (55.4 to 68.1) |
| 24 hours postdose | 77.2 (71.7 to 82.1) | 77.3 (72.0 to 82.1) | 75.1 (69.2 to 80.4) | 82.9 (77.5 to 87.5) |
The percentage of subjects with their Screening MBS (most bothersome symptoms) among nausea, photophobia, and phonophobia (from eDiary data collection) absent at 15, 30, and 45 minutes and 1, 1.5, 2 (DB2 period), 4, and 24 hours postdose during each DB treatment period were summarized by treatment group and time point.
| percentage of subjects | Placebo DB1 | DFN-15 DB1 | Placebo DB2 | DFN-15 DB2 |
|---|---|---|---|---|
| 15 minutes postdose | 10.6 (6.8 to 15.6) | 6.3 (3.4 to 10.5) | 8.0 (4.4 to 13.1) | 8.9 (5.2 to 14.1) |
| 30 minutes postdose | 17.4 (12.7 to 23.0) | 17.3 (12.6 to 22.9) | 15.8 (10.9 to 21.8) | 22.9 (17.1 to 29.5) |
| 45 minutes postdose | 22.5 (17.2 to 28.5) | 28.5 (22.7 to 34.8) | 27.5 (21.3 to 34.3) | 36.8 (30.0 to 44.1) |
| 1 hour postdose | 25.0 (19.5 to 31.1) | 39.6 (33.2 to 46.2) | 35.8 (29.0 to 43.0) | 44.7 (37.5 to 52.1) |
| 1.5 hours postdose | 38.7 (32.4 to 45.3) | 49.1 (42.5 to 55.8) | 42.6 (35.5 to 49.8) | 53.4 (46.1 to 60.6) |
| 2 hours postdose | 44.8 (38.3 to 51.5) | 57.8 (51.1 to 64.2) | 50.0 (42.8 to 57.2) | 63.4 (56.1 to 70.2) |
| 4 hours postdose | 61.3 (54.7 to 67.5) | 67.4 (61.0 to 73.4) | 60.7 (53.5 to 67.6) | 78.0 (71.5 to 83.7) |
| 24 hours postdose | 86.0 (80.9 to 90.2) | 82.5 (77.0 to 87.1) | 83.7 (77.7 to 88.6) | 89.6 (84.4 to 93.5) |
The values of the functional disability scale were: 0=no disability, able to function normally; 1=performance of daily activities mildly impaired, can still do everything but with difficulty; 2=performance of daily activities moderately impaired, unable to do some things; 3=performance of daily activities severely impaired, cannot do all or most things, bed rest may be necessary. A decrease in values indicates improvement from baseline.
| units on a scale | Placebo DB1 | DFN-15 DB1 | Placebo DB2 | DFN-15 DB2 |
|---|---|---|---|---|
| 2 hours postdose | -0.7 ± 0.94 | -0.9 ± 1.00 | -0.6 ± 0.83 | -0.9 ± 0.87 |
| 4 hours postdose | -1.1 ± 0.99 | -1.3 ± 1.01 | -1.0 ± 0.95 | -1.2 ± 0.94 |
| 24 hours postdose | -1.8 ± 0.82 | -1.7 ± 0.84 | -1.5 ± 0.86 | -1.5 ± 0.88 |
The percentage of subjects who were pain-free at 2 and 4 hours postdose during each DB treatment period among those subjects reporting cutaneous allodynia before dosing were summarized by treatment group and time point.
| percentage of subjects | Placebo DB1 | DFN-15 DB1 | Placebo DB2 | DFN-15 DB2 |
|---|---|---|---|---|
| 2 hours postdose | 19.2 (9.6 to 32.5) | 38.0 (24.7 to 52.8) | 31.0 (17.6 to 47.1) | 54.3 (39.0 to 69.1) |
| 4 hours postdose | 45.3 (31.6 to 59.6) | 56.0 (41.3 to 70.0) | 40.5 (25.6 to 56.7) | 56.5 (41.1 to 71.1) |
The percentage of subjects who were pain-free at 2 and 4 hours postdose whose BMI was \<30 kg/m2 vs. subjects whose BMI was ≥30 kg/m2 during each DB treatment period were summarized by treatment group and time point.
| percentage of subjects | Placebo DB1 | DFN-15 DB1 | Placebo DB2 | DFN-15 DB2 |
|---|---|---|---|---|
| 2 hours postdose (BMI<30) | 22.1 (15.8 to 29.7) | 31.5 (24.1 to 39.7) | 26.8 (19.7 to 34.8) | 41.9 (32.8 to 51.4) |
| 4 hours postdose (BMI <30) | 41.7 (33.8 to 50.0) | 55.9 (47.4 to 64.1) | 50.0 (41.5 to 58.5) | 67.8 (58.6 to 76.1) |
| 2 hours postdose (BMI>=30) | 21.1 (14.0 to 29.7) | 40.3 (31.8 to 49.3) | 37.3 (27.9 to 47.4) | 50.4 (41.2 to 59.6) |
| 4 hours postdose (BMI>=30) | 47.8 (38.4 to 57.3) | 56.9 (48.0 to 65.6) | 50.0 (39.9 to 60.1) | 56.2 (46.9 to 65.2) |
Headache pain recurrence was defined as pain-free at 2 hours postdose with pain reported as mild, moderate, or severe at 24 hours postdose. This outcome measure shows percentage of subjects who reported pain-free status and 2 hours postdose but subsequently reported recurrent pain at 24 hours postdose.
| percentage of subjects | Placebo DB1 | DFN-15 DB1 | Placebo DB2 | DFN-15 DB2 |
|---|---|---|---|---|
| Headache Pain Recurrence Postdose (DB1 and DB2) | 14.0 (6.3 to 25.8) | 9.2 (4.3 to 16.7) | 6.6 (2.2 to 14.7) | 6.4 (2.6 to 12.7) |
Sustained headache pain relief was defined as pain relief at 2 hours postdose with no use of rescue medication and no worsening of headache pain within 2 to 24 hours postdose. This outcome measure shows the percentage of subjects who reported pain relief at 2 hours postdose with no use of rescue medication or worsening of headache pain through 24 hours postdose.
| percentage of subjects | Placebo DB1 | DFN-15 DB1 | Placebo DB2 | DFN-15 DB2 |
|---|---|---|---|---|
| Sustained Headache Pain Relief Postdose (DB1 and DB2) | 43.4 (36.6 to 50.4) | 55.1 (48.0 to 62.1) | 49.7 (42.4 to 57.1) | 60.2 (52.8 to 67.3) |
Sustained headache pain freedom was defined as pain-free at 2 hours postdose, with no use of rescue medication and no recurrence of headache pain within 2 to 24 hours postdose. This outcome measure shows percentage of subjects who were pain-free at 2 hours postdose without the use of rescue medication or recurrence of headache pain through 24 hours postdose.
| percentage of subjects | Placebo DB1 | DFN-15 DB1 | Placebo DB2 | DFN-15 DB2 |
|---|---|---|---|---|
| Sustained Headache Pain Freedom Postdose (DB1 and DB2) | 17.0 (12.2 to 22.7) | 26.8 (20.9 to 33.4) | 26.5 (20.3 to 33.3) | 39.8 (32.7 to 47.2) |
The percentage of subjects who used rescue mediation after 2 hours (2 to 24 hours) postdose compared between DFN-15 and placebo in each DB period.
| percentage of subjects | Placebo DB1 | DFN-15 DB1 | Placebo DB2 | DFN-15 DB2 |
|---|---|---|---|---|
| Use of Rescue Medication Postdose (DB1 and DB2) | 30.1 (24.7 to 36.0) | 15.8 (11.7 to 20.7) | 18.4 (13.7 to 23.8) | 16.7 (12.2 to 22.0) |
Subject-rated treatment overall satisfaction was based on a 7-point scale at 2 and 4 hours postdose during each DB treatment period. The difference between the subject-rated study drug treatment satisfaction score at 2 and 4 hours postdose and the baseline PPMQ-R (Patient Perception of Migraine Questionnaire) response for the same question were summarized by treatment group (global satisfaction item at baseline asked about the subject's usual migraine treatment). The possible values of the subject treatment satisfaction scale were: 1=very satisfied, 2=satisfied, 3=somewhat satisfied, 4=neither satisfied nor dissatisfied, 5=somewhat dissatisfied, 6=dissatisfied, 7=very dissatisfied. A decrease in values indicates improvement from baseline.
| units on a scale | Placebo DB1 | DFN-15 DB1 | Placebo DB2 | DFN-15 DB2 |
|---|---|---|---|---|
| 2 hours postdose | 3.9 ± 1.90 | 3.3 ± 1.78 | 3.6 ± 1.97 | 3.1 ± 1.85 |
| 4 hours postdose | 3.7 ± 2.05 | 3.2 ± 1.90 | 3.5 ± 2.06 | 2.9 ± 1.80 |
Patient Perception of Migraine Questionnaire-Revised had 30 questions assessing subject's satisfaction with migraine medication, including 3 global items \& 4 subscales (i.e., efficacy, function, ease of use, tolerability). A 5-point scale (1-Not At All to 5-Extremely) was used for tolerability subscale questions; a 7-point scale (1-Very Satisfied to 7-Very Dissatisfied) was used for all other subscales and global items. Total score was average of efficacy/function/ease of use subscale scores. Each subscale \& total scores were transformed to range from 0-100, with higher scores indicating better satisfaction or tolerability. Total raw score/global items were not transformed. The total raw score could range from 17 (min) to 119 (max), with lower scores indicating better satisfaction. Change from baseline scores at 24-hour-postdose for each subscale score, global item score, total score, \& total raw score were summarized by treatment group below.
| units on a scale | Placebo DB1 | DFN-15 DB1 | Placebo DB2 | DFN-15 DB2 |
|---|---|---|---|---|
| Total Score | -0.657 ± 30.9929 | 4.367 ± 33.7146 | 3.544 ± 32.3791 | 3.940 ± 31.7753 |
| Total Raw Score | 0.835 ± 12.0599 | -1.254 ± 12.9334 | -0.744 ± 12.3973 | -1.448 ± 12.3105 |
| Efficacy | -4.196 ± 39.0051 | 2.292 ± 40.8958 | 0.385 ± 39.7293 | 3.604 ± 39.9214 |
| Function | -0.020 ± 40.3093 | 7.931 ± 42.8913 | 6.239 ± 39.8213 | 8.169 ± 38.6639 |
| Ease of Use | 2.247 ± 28.5348 | 2.876 ± 29.3816 | 4.009 ± 28.6588 | 0.047 ± 28.8880 |
| Tolerability | 5.99 ± 16.521 | 8.45 ± 15.930 | 9.01 ± 15.301 | 6.72 ± 15.565 |
| Medication Effectiveness (Global Item) | 0.7 ± 2.59 | 0.2 ± 2.77 | 0.2 ± 2.64 | 0.2 ± 2.63 |
| Side Effects (Global Item) | -0.3 ± 2.05 | 2.6 ± 1.36 | -0.7 ± 1.88 | -0.3 ± 1.92 |
| Overall Satisfaction (Global Item) | 0.5 ± 2.67 | 0.1 ± 2.75 | 0.1 ± 2.62 | 0.0 ± 2.48 |
Collected over Per protocol, the maximum dosing timeframe for DB2 was 10 weeks; therefore, the maximum AE collection window was 11 weeks total.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo DB1 | 0/282 (0%) | 2/282 (0.7%) | 9/282 (3.2%) |
| DFN-15 DB1 | 0/285 (0%) | 0/285 (0%) | 17/285 (6%) |
| Placebo DB2 | 0/249 (0%) | 0/249 (0%) | 5/249 (2%) |
| DFN-15 DB2 | 0/244 (0%) | 0/244 (0%) | 6/244 (2.5%) |
| Overall | 0/567 (0%) | 2/567 (0.4%) | 37/567 (6.5%) |
| Event | Placebo DB1 | DFN-15 DB1 | Placebo DB2 | DFN-15 DB2 | Overall |
|---|---|---|---|---|---|
| Road traffic accidentInjury, poisoning and procedural complications | 1/282 | 0/285 | 0/249 | 0/244 | 1/567 |
| Non-cardiac chest painNervous system disorders | 1/282 | 0/285 | 0/249 | 0/244 | 1/567 |
| Event | Placebo DB1 | DFN-15 DB1 | Placebo DB2 | DFN-15 DB2 | Overall |
|---|---|---|---|---|---|
| DysgeusiaNervous system disorders | 4/282 | 12/285 | 2/249 | 4/244 | 22/567 |
| NauseaGastrointestinal disorders | 5/282 | 9/285 | 3/249 | 2/244 | 19/567 |
Baseline characteristics list the safety population (i.e., all subjects who were dosed during DB1). Note that there are 2 subjects in the placebo group and 2 subjects in the DFN-15 group, for whom no postdose efficacy data were collected. These individuals are, therefore, included in the baseline subject counts but are not included subsequent results reporting.
| Age, Continuous(years) | DB1 Placebo | DB1 DFN-15 | Total |
|---|---|---|---|
| Mean | 40.1 ± 12.59 | 40.5 ± 11.68 | 40.3 ± 12.12 |
| Sex: Female, Male(Participants) | DB1 Placebo | DB1 DFN-15 | Total |
|---|---|---|---|
| Female | 242 | 252 | 494 |
| Male | 40 | 33 | 73 |
| Ethnicity (NIH/OMB)(Participants) | DB1 Placebo | DB1 DFN-15 | Total |
|---|---|---|---|
| Hispanic or Latino | 38 | 40 | 78 |
| Not Hispanic or Latino | 243 | 242 | 485 |
| Unknown or Not Reported | 1 | 3 | 4 |
| Race (NIH/OMB)(Participants) | DB1 Placebo | DB1 DFN-15 | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 6 | 5 | 11 |
| Native Hawaiian or Other Pacific Islander | 0 | 2 | 2 |
| Black or African American | 50 | 75 | 125 |
| White | 219 | 198 | 417 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 7 | 4 | 11 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
The record gives a start of Dec 2016, a primary completion of Nov 2017 and a completion of May 2019. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2023, 5 years 2 months after primary completion. A results delay was requested in Dec 2018.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
BioDelivery Sciences International